Variability Of Gait Parameters In Patients With Multiple Sclerosis

Multiple sclerosis (MS) is the most frequent neurological disease causing permanent disability in young adults. Subtle walking difficulties, such as reduced walking speed, step length, cadence and increased step width can be detected at an early stage of the disease. Main goal of this research is by using non-invasive wireless inertial sensors measure gait of MS patients in clinical setting and extract temporal biomechanical parameters that would allow objectively evaluate level of disability in MS patients. Analysis of 25-Foot walk showed that the duration of stance phase is approximately 1.6 times greater in MS group than in healthy control group, while the duration of swing phase in MS group is 1.3 times longer. In general, the MS patients are walking approximately 1.6 times slower.

Download Full-text

Path feel smart insoles are a reliable tool to estimate gait parameters for monitoring multiple sclerosis patients progression

Journal of the Neurological Sciences ◽

10.1016/j.jns.2021.118174 ◽

2021 ◽

Vol 429 ◽

pp. 118174

Author(s):

Juan Manuel Völker ◽

Ingvar Kiricenko ◽

Nuala Burke

Keyword(s):

Multiple Sclerosis ◽

Reliable Tool ◽

Gait Parameters ◽

Multiple Sclerosis Patients

Download Full-text

Gait parameters and lower limb joint kinematics of multiple sclerosis subjects undergoing a gait training based on treadmill and virtual reality

Gait & Posture ◽

10.1016/j.gaitpost.2012.12.031 ◽

2013 ◽

Vol 37 ◽

pp. S7-S8 ◽

Cited By ~ 1

Author(s):

A. Peruzzi ◽

A. Cereatti ◽

E. Aiello ◽

U. Della Croce ◽

A. Mirelman

Keyword(s):

Multiple Sclerosis ◽

Virtual Reality ◽

Lower Limb ◽

Gait Training ◽

Joint Kinematics ◽

Gait Parameters

Download Full-text

Gait Mechanics Are Different Between Healthy Controls and Patients With Multiple Sclerosis

Journal of Applied Biomechanics ◽

10.1123/jab.29.3.303 ◽

2013 ◽

Vol 29 (3) ◽

pp. 303-311 ◽

Cited By ~ 30

Author(s):

Jessie M. Huisinga ◽

Kendra K. Schmid ◽

Mary L. Filipi ◽

Nicholas Stergiou

Keyword(s):

Multiple Sclerosis ◽

Joint Torque ◽

Group Differences ◽

Healthy Controls ◽

Joint Power ◽

Joint Torques ◽

Gait Parameters ◽

Healthy Control ◽

Gait Mechanics ◽

Walking Velocity

Multiple sclerosis (MS) causes severe gait problems in relatively young individuals, yet there have been limited studies to quantitatively identify the specific gait parameters that are affected. The purpose of this study was to define any differences in biomechanical gait parameters between patients with MS and healthy controls. A total of 31 MS patients and 31 healthy controls were evaluated: joint torques and joint powers were calculated at the ankle, knee, and hip during the stance phase of gait. The self-selected walking velocity was used as a covariate in the analysis to ensure that group differences were not due to differences in walking velocity between the MS and healthy control groups. Reduced angular range, less joint torque, and reduced joint power were seen in patients with MS. We also found significant correlations between biomechanical gait parameters and EDSS score, which provides a clinical rating of disease severity. Our findings provide a quantitative assessment of the gait mechanics employed in patients with MS. The altered lower extremity mechanics observed in patients with MS reflect both a neurological and strength deficit compared with healthy controls during walking.

Download Full-text

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Multiple Sclerosis Journal ◽

10.1177/1352458517720043 ◽

2017 ◽

Vol 24 (10) ◽

pp. 1337-1346 ◽

Cited By ~ 12

Author(s):

Francisco Alejandro Rodriguez-Leal ◽

Rocco Haase ◽

Katja Thomas ◽

Judith Christina Eisele ◽

Undine Proschmann ◽

...

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Primary Objective ◽

European Medicines Agency ◽

Gait Assessment ◽

Real World Setting ◽

Large Patient ◽

New Information ◽

Gait Parameters ◽

Disability Status

Objective: The primary objective of this real-world study was to describe the response to fampridine and changes of gait parameters in multiple sclerosis (MS) patients’ walking disability (Expanded Disability Status Scale (EDSS): 4–7) after treatment with fampridine for 2 weeks as recommended by the European Medicines Agency (EMA) and compare it with the overall physician’s judgement. Methods: A total of 211 adult MS patients were analyzed using a multimodal gait assessment including the timed 25-foot walk test (T25FW), 2-minute walking test (2-MWT), 12-item Multiple Sclerosis Walking Scale (MSWS-12), the GAITRite electronic walkway system, and the patients’ clinical global impression (CGI). Multimodal gait assessment was compared with the clinician’s impression of overall improvement after 2 weeks. Results: In total, 189 subjects were included, of which 133 (70.37%) were responders to fampridine (RF), according to physician’s judgement. Looking at independent multimodal gait assessment, RFs showed improvement of 12.60% in the T25FW, 19.25% in the 2-MWT, 21.12% in the MSWS-12, and 6.54% in their Functional Ambulation Profile (FAP) score. The combination of the T25FW and the MSWS-12 would offer the best sensitivity and specificity for determining response to fampridine according to both neurologists’ and patients’ classification. Conclusion: This study provides new information on the use of fampridine in a real-world setting with a large patient sample on the potential benefit of using more definitive responder criteria to fampridine for the clinical setting.

Download Full-text